Latest News & Features
Americas
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction. 20 May 2019
Europe
Two references to the Court of Justice of the European Union should help clarify the position on what exactly is eligible for a supplementary protection certificate, as Michael Pears and Joel Beevers of Potter Clarkson explain. 20 May 2019
Americas
3D-printed organs and tissues are now a reality, but questions remain over their patentability, says Gabriel Di Blasi of Di Blasi, Parente & Associados. 20 May 2019
Americas
While registering trademarks for cannabis products at the USPTO is currently impossible, brands are applying creative solutions to the problem, says Leon Steinberg of Dennemeyer. 20 May 2019
Americas
The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch. 20 May 2019
Americas
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law. 20 May 2019
Asia
An upcoming case on the patent eligibility of genetically modified seed in India will have far-reaching ramifications, as Archana Shankar and Gitika Suri of Anand & Anand explain. 20 May 2019
Americas
It is challenging but not impossible to protect software innovations in Mexico, according to Alejandro Moreno Hernández of Uhthoff, Gomez Vega & Uhthoff. 20 May 2019
Americas
Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid. 20 May 2019
article
The High Court of Delhi has ruled that the test for passing off of so-called nutraceuticals should be the same as that for pharmaceuticals. 20 May 2019